EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Mycophenolate mofetil (MMF) for refractory chronic graft versus host disease (cGvHD)



Mycophenolate mofetil (MMF) for refractory chronic graft versus host disease (cGvHD)



Haematologica 88(8): Elt28; Author Reply Elt29-Elt28; Author Reply Elt29




(PDF emailed within 1 workday: $29.90)

Accession: 049646127

Download citation: RISBibTeXText

PMID: 12935991



Related references

The use mycophenolate mofetil in the treatment of refractory chronic graft versus host disease. Blood 92(10 SUPPL 1 PART 1-2): 346B, Nov 15, 1998

Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease. Haematologica 88(7): 837-839, July, 2003

Salvage therapy with mycophenolate mofetil and FK-506 for refractory chronic graft-versus-host disease. Blood 92(10 SUPPL 1 PART 1-2): 457A, Nov 15, 1998

Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplantation 24(5): 517-520, Sept 1, 1999

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Annals of Hematology 84(10): 681-685, 2005

Mycophenolate mofetil as salvage treatment for steroid-refractory chronic graft versus-host disease in children. Blood 98(11 Part 1): 398a, November 16, 2001

Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. International Journal of Hematology 83(1): 80-85, 2006

Mycophenolate mofetil as rescue therapy for high-risk steroid-refractory chronic graft versus-host-disease. Pediatric Research 53(4 Part 2): 275A, April, 2003

Benefits of mycophenolate mofetil for refractory graft-versus-host disease. Japanese Journal of Clinical Hematology 48(8): 624-631, 2007

Revisiting mycophenolate mofetil for steroid-refractory acute graft-versus-host disease: Is higher dosing effective in children?. Pediatric Transplantation 19(6): 582-583, 2016

Mycophenolate mofetil for the treatment of chronic graft versus host disease of the liver. Blood 94(10 SUPPL 1 PART 1): 159a, Nov 15, 1999

Treatment of acute and chronic graft versus host disease with mycophenolate mofetil. Blood 94(10 SUPPL 1 PART 2): 368b, Nov 15, 1999

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 11(4): 307-313, 2005

Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation. Pediatric Transplantation 19(6): 652-658, 2016

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 113(21): 5074-5082, 2009